News | November 09, 2011

Ticagrelor Receives Class I Recommendation in New U.S. Guidelines for PCI

November 9, 2011 – AstraZeneca announced that a combined expert committee of American College of Cardiology Foundation (ACCF), American Heart Association (AHA) and Society for Cardiovascular Angiography and Interventions (SCAI) has updated its guidelines for the management of patients undergoing percutaneous coronary intervention (PCI) to provide a Class I recommendation for giving the oral antiplatelet medicine, Brilinta (ticagrelor) tablets for patients undergoing PCI.

"Class I" means that a given "procedure/treatment should be performed/administered" to patients, given it was found to be "useful/effective/beneficial." Class I is the highest recommendation provided by the guidelines committee.

In patients with acute coronary syndrome (ACS), Brilinta is the first and only oral antiplatelet U.S. Food and Drug Administration (FDA)-approved to significantly reduce cardiovascular (CV) death versus clopidogrel. Brilinta significantly reduced the primary composite end point of CV death, myocardial infarction (MI), or stroke versus clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. The secondary end points included the individual components of CV death, MI, and stroke. In patients treated with PCI, it also reduces the rate of stent thrombosis.

Brilinta has been studied in ACS in combination with aspirin. Maintenance doses of aspirin >100 mg decreased the effectiveness of Brilinta. Avoid maintenance doses of aspirin >100 mg daily.

Specifically, the 2011 ACCF/AHA/SCAI Guidelines for PCI state that:

Class I:

A loading dose of a P2Y12 receptor inhibitor should be given to patients undergoing PCI with stenting (Level of Evidence: A)

Options include:

·  Clopidogrel 600 mg (ACS and non-ACS patients) (Level of Evidence: B)

·  Prasugral 60 mg (ACS patients) (Level of Evidence: B)

·  Ticagrelor 180 mg (ACS patients) (Level of Evidence: B)

The duration of P2Y12 inhibitor therapy after stent implantation should generally be as follows:

·  In patients receiving a stent (bare-metal stent [BMS] or drug-eluting stent [DES]) during PCI for ACS, P2Y12 inhibitor therapy should be given for at least 12 months. Options include clopidogrel 75 mg daily, prasugrel 10 mg daily, and ticagrelor 90 mg twice daily. (Level of Evidence: B)

 

Class IIa:

·  After PCI, it is reasonable to use aspirin 81 mg per day in preference to higher maintenance doses. (Level of Evidence: B)

 

2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery:

In addition, the 2011 ACCF/AHA Guidelines for Coronary Artery Bypass Graft (CABG) Surgery were also released today and notes as Class I that aspirin should be administered to CABG patients preoperatively (Level of Evidence: B), and that in patients referred for elective CABG, clopidogrel and ticagrelor should be discontinued for at least 5 days before surgery (Level of Evidence: B) and prasugrel for at least seven days (Level of Evidence: C) to limit blood transfusions.

Brilinta received approval from the FDA on July 20, 2011, and is indicated to reduce the rate of thrombotic cardiovascular (CV) events in patients with acute coronary syndrome (ACS) (unstable angina [UA], non–ST-elevation myocardial infarction [NSTEMI], or ST-elevation myocardial infarction [STEMI]). Brilinta has been shown to reduce the rate of a combined end point of CV death, MI, or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with an artery-opening procedure known as percutaneous coronary intervention (PCI), Brilinta reduces the rate of stent thrombosis.

On Nov. 3, 2011, AHA/ACCF revised their Guidelines on Secondary Prevention and Risk Reduction Therapy to include Brilinta, in combination with low-dose aspirin, as a Class I therapy to be taken twice daily for at least 12 months in patients receiving a BMS or DES during PCI for ACS.

The revised guidelines are available online and will be published in the Dec. 6, 2011, issues of the Journal of the American College of Cardiology and Circulation: Journal of the American Heart Association.  The guideline for PCI will also be published in the December 2011 issue of Catheterization and Cardiovascular Interventions.

For more information: www.cardiosource.org, www.heart.org, and www.scai.org

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Overlay Init